The first oral therapy for adults and children aged 2 months or older who have spinal muscular atrophy (SMA) has received FDA approval.
A fatal genetic disease that leads to severe muscle weakness, SMA affects about 1 in 8000 to 10 000 people worldwide. Infants with SMA can have difficulty sitting upright, controlling their head movements, swallowing, and breathing. Children with the most common form, type 1, typically do not survive past early childhood.
Jaklevic MC. Oral Drug Approved for Spinal Muscular Atrophy. JAMA. 2020;324(11):1026. doi:10.1001/jama.2020.16783
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: